Pharmaceutical Technology

MARCH 10, 2023

Pharmaceutical and biotechnology industries widely use freeze-drying systems to protect vaccines, antibodies, antibiotics such as penicillin, blood plasma, proteins, enzymes, hormones, viruses, and bacteria from heat and minimise their biological activity.

Manufacturing 147

Manufacturing Production Containment Antibody 147

Scienmag

MAY 18, 2021

Advancing PDT as a rapid response to pandemics Credit: Vladislav Yakovlev/Texas A&M University WASHINGTON, May 18, 2021 — The COVID-19 pandemic has reinforced the pressing need to mitigate a fast-developing virus as well as antibiotic-resistant bacteria that are growing at alarming rates worldwide.

Bacteria 53

Bacteria Antibody Development Engineer 53

XTalks

JANUARY 6, 2021

Researchers at the National Institutes of Health (NIH) in the US have isolated small antibodies called “nanobodies” from a llama named Cormac that can block the SARS-CoV-2 coronavirus. Nanobodies are about a quarter of the size, and approximately one tenth of the weight, of a typical human antibody.

Antibody 105

Antibody Protein Bacteria In-Vitro 105

The Pharma Data

DECEMBER 31, 2020

Antibodies Respond Differently to Severe Versus Mild COVID-19. Researchers at Stanford Medicine found that COVID-19 antibodies preferentially target different parts of the SARS-CoV-2 virus in mild COVID-19 cases than they do in severe cases. People with severe COVID-19 have low proportions of antibodies that target the spike protein.

Antibody 52

Antibody Research Bacteria Genetics 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

Delveinsight

NOVEMBER 26, 2020

Genmab discards antibody-drug conjugate after the early-phase fiasco. Genmab is ditching an antibody-drug conjugate after it flunked the mark in early-phase trials. The latter can usually resist Pseudomonas infections, but as they target a broad spectrum of bacteria, can also contribute to the increase of antibiotic-resistant bugs.

Antibody 79

Antibody Trials Drugs Engineer 79

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Vaccine 130

Vaccine Vaccination Containment Immune Response 130

XTalks

JULY 25, 2023

The bacteria usually enter the body through wounds, but infection can also occur through contaminated meat or inhalation of spores. Cyfendus functions by stimulating the production of antibodies targeted against the protective antigen protein. Anthrax is a rare, yet severe disease caused by the bacterium B. Overall, 66.3

FDA Approval 98

FDA Approval Vaccine Vaccination Antibody 98

XTalks

JULY 14, 2021

CDIs typically develop after the use of antibiotics, which can wipe out the gut’s healthy bacteria. Seres’ microbiome drug SER-109 aims to restore the healthy bacteria via an oral capsule that contains a protective species of gut bacteria. Difficile infection (CDI). Read the full articles here: .

Bacteria 52

Bacteria Marketing Drugs Containment 52

BioTech 365

OCTOBER 5, 2020

.–(BUSINESS WIRE)–The Gold Standard Diagnostics Group (GSD) today announced the immediate availability of their two new Lyme IgG and Lyme IgM EIA kits for detection of antibodies against Lyme disease causing bacteria. The two assays give laboratories a more … Continue reading →

Bacteria 40

Bacteria Antibody 40

Scienmag

NOVEMBER 17, 2020

New research published in Arthritis & Rheumatology suggests that immune responses to certain bacteria that cause periodontal disease may play a role in patients’ higher cardiovascular disease risk. Among 197 patients with rheumatoid arthritis, those with antibody responses to common […].

Immune Response 40

Immune Response Bacteria Antibody Research 40

XTalks

AUGUST 2, 2022

Benlysta (belimumab) is a biologic therapy, a human monoclonal antibody. Autoreactive B cells release antibodies like other B cells do, except they release autoantibodies. The autoantibodies do not fight actual infection or bacteria, but rather the normal tissue in the body. How Benlysta (belimumab) Works.

FDA Approval 94

FDA Approval Antibody Bacteria Protein 94

Roots Analysis

FEBRUARY 27, 2024

What are Affimers : Affimers are small proteins that target and bind molecules on cellular surfaces in a manner analogous to monoclonal antibodies. In nature, they are made by a group of bacteria known as actinomycetes. The key difference is that affimers are optimized to enhance their structural stability.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

pharmaphorum

AUGUST 7, 2020

LRRK2 regulates lysosomes, which play a vital role in cell function by breaking down excess or worn-out cell parts, and can also destroy invading viruses and bacteria. Mutations in the LRRK2 gene can cause Parkinson’s disease.

Bacteria 69

Bacteria Marketing Licensing Licensing 69

The Pharma Data

MARCH 8, 2021

OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick. The main safety and immunogenicity readout (Primary Endpoint analysis) will be at Month 7, where peak antibody titers are expected. VLA15 has demonstrated strong immunogenicity and safety data in pre-clinical and clinical studies so far.

Vaccine 52

Vaccine Vaccination Bacteria Protein 52

The Pharma Data

SEPTEMBER 30, 2021

Nirsevimab is being developed by Sanofi and AstraZeneca and is being evaluated because the first investigational long-acting antibody designed to assist prevent lower tract infection (LRTI) caused by RSV altogether infants from birth up to 12 months aged during their first RSV season. In the U.S., About MenQuadfi In the U.S.,

Vaccine 52

Vaccine Vaccination Research Antibody 52

pharmaphorum

JULY 14, 2021

Last year, Pfizer made almost $6 billion from its Prevnar 13 vaccine, which covers 13 common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. That is equivalent to 14% of Pfizer’s total revenues.

Immune Response 52

Immune Response Vaccine Vaccination Protein 52

Roots Analysis

OCTOBER 16, 2023

Biopharmaceutical filtration is a critical step in the production of biopharmaceuticals, including proteins, antibodies, and vaccines. Membrane Filters: Membrane filters are typically used for sterilization and removal of smaller impurities such as bacteria and viruses. are used to remove any residual bacteria, viruses, or endotoxins.

Bacteria 40

Bacteria Production Protein Contamination 40

The Pharma Data

JUNE 30, 2021

In our study, we measured the humoral response – so the level of antibodies – in naturally exposed cats,” relays Yasmin Parr. To achieve this, she developed a novel ELISA (Enzyme-linked Immunosorbent Assay) to measure a certain antibody type directed towards a specific protein of the virus.

Scientist 52

Scientist Immune Response Antibody Development 52

The Pharma Data

APRIL 22, 2023

Plasma cells produce antibodies that protect the body from invasive foreign substances, such as bacteria and viruses. In recent years, there has also been an increase in the use of anti-CD38 antibodies in combination with immunomodulatory agents or proteasome inhibitors for the initial treatment or at the first relapse.

Antibody 40

Antibody Protein Bacteria Drugs 40

The Pharma Data

JULY 21, 2021

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi , the bacteria that cause Lyme disease. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Vaccination Trials Bacteria 52

pharmaphorum

MAY 31, 2022

Last year, Affinivax reported positive phase 2 results with ASP3772, which targets 24 of the common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. GSK said it is paying $2.1

Vaccine 52

Vaccine Vaccination Bacterium Sales 52

The Pharma Data

APRIL 26, 2022

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Vaccination Bacteria Protein 52

The Pharma Data

DECEMBER 31, 2020

Previous studies have raised concern that COVID-19 patients might lose their immunity quickly once they recover, because the first wave of coronavirus antibodies tends to wane after the first few months. THURSDAY, Dec. Memory B cells specific to COVID-19 were found in samples taken 242 days after symptom onset, the results showed.

Vaccine 52

Vaccine Vaccination Antibody Immune Response 52

The Pharma Data

DECEMBER 2, 2020

aeruginosa bacteria, instead of killing the bacteria as an antibiotic would aim to do. Tubulis – Germany’s Tubulis formed a strategic collaboration with WuXi STA and WuXi Biologics to manufacture and advance Tubulis’ next generation antibody-drug conjugates (ADCs) towards IND-enabling studies. in Mainland China.

Drugs 52

Drugs Gene Editing Genome Genomics 52

XTalks

AUGUST 18, 2021

Also important are the environmental changes that take place in the lung tissue during infection with SARS-CoV-2; the buildup of fluid and pus in pulmonary alveoli can provide a hospitable breeding ground for pathogenic bacteria. This is consistent with autopsy reports from previous pandemics, including the influenza pandemic of 1918.

Development 105

Development Bacteria Drugs Vaccine 105

The Pharma Data

OCTOBER 26, 2020

AR-711 is a fully human immunoglobulin 1, or IgG1, monoclonal antibody discovered from screening the antibody secreting B-cells of convalescent COVID-19 patients. He will address the preclinical performance of AR-711, the advantages of direct lung delivery using nebulized aerosols, and the COVID-19 clinical program. About AR-711.

Antibody 52

Antibody Genetic Engineering Development Clinical Trials 52

Pfizer

FEBRUARY 16, 2023

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease. OspA is a surface protein expressed by the bacteria when present in a tick. FDA in July 2017.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccine Vaccination 76

pharmaphorum

OCTOBER 27, 2021

There was bad news for Lilly elsewhere is its Alzheimer’s pipeline as it announced the demise of anti-tau protein antibody zagotenemab, which had reached phase 2 but failed to have an impact on its primary endpoint. Cortexyme trial disappoints.

Trials 52

Trials Drugs Sales Bacteria 52

The Pharma Data

MARCH 13, 2022

CD8+ T cells are nicknamed killer T cells (they’re also known as cytotoxic T cells) for their ability to eliminate foreign invaders such as bacteria and viruses from the body. The team’s study was published March 1, 2022, in mBio, a journal from the American Society for Microbiology.

Immune Response 52

Immune Response Protein Medicine Genetics 52

XTalks

JANUARY 20, 2021

Ovalbumin led to increased dietary-antigen-specific IgE antibodies in the mice that were limited to the intestine. The researchers pieced together the events and were able to link the observed upregulation of IgE antibodies, activation of mast cells and histamine release to ingestion of the ovalbumin to an increase visceral pain.

Immune Response 52

Immune Response Research Allergies Protein 52

The Pharma Data

DECEMBER 15, 2020

On top of this, another 8 million carry auto-antibodies, blood molecules that indicate a person’s chance of developing an autoimmune disease. Monoclonal Antibodies. The human monoclonal antibody targets specific immune plasma cells. The cells secrete auto-antibodies, but do not respond to standard immunosuppression.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Trials 52

XTalks

DECEMBER 17, 2021

Initial lab studies, including one from South Africa, show that vaccine-induced antibodies may be less effective at neutralizing Omicron. Early lab data also shows that Omicron can be more effectively neutralized with three doses of the Pfizer vaccine, and that two doses provides only about 70 percent protection against hospitalization.

Life Science 98

Life Science Vaccine Vaccination Trials 98

The Pharma Data

OCTOBER 19, 2020

Diagnostics Update : To-date the FDA has authorized 282 individual EUAs, which include 220 molecular tests, 56 antibody tests and 6 antigen tests. . In a challenge trial, people are given a vaccine then intentionally dosed with the virus or bacteria that causes the disease. Diagnostics.

Vaccine 52

Vaccine Vaccination Trials Clinical Trials 52

The Pharma Data

DECEMBER 13, 2020

Both patients experienced disease progression on immunotherapy with anti- PD-1/PDL-1 antibodies prior to enrollment in the study. . Evidence of durable stable disease was observed in two patients being treated for metastatic melanoma and metastatic small cell lung cancer. Sokolovska, A.,

Immune Response 40

Immune Response Engineer Medicine Clinical Trials 40

XTalks

APRIL 12, 2021

According to the company’s pipeline page, the antibody drug is still in the drug discovery stage of development. Research suggests that some gut bacteria can increase levels of ?-synuclein The deal is worth $560 million in upfront payments, with an addition $465 million in the form of an equity investment into Denali.

Gene Therapy 96

Gene Therapy Gene Trials Development 96

The Pharma Data

SEPTEMBER 8, 2021

Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine. September 8, 2021. BOTOX ® (onabotulinumtoxinA).

Botox 52

Botox Doctors Doctor Medicine 52